Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Pliant Therapeutics Inc PLRX

Healthcare Biotechnology
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PLRX)

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

GlobeNewswire 9 days ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire 12 days ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 6, 2025

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

GlobeNewswire August 7, 2025

Pliant Therapeutics Provides Update on BEACON-IPF

GlobeNewswire June 27, 2025

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

GlobeNewswire May 21, 2025

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

GlobeNewswire May 8, 2025

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

GlobeNewswire May 1, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

ACCESS Newswire April 26, 2025
View More News ››

Opinion & Analysis (NDAQ:PLRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PLRX)

Sell buddy sell.

This stock is signalling a big downtrend this morning.
coolfooldumbguy - February 10, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX): A Promising Biophar

http://beyondspx.com/2024/08/02/pliant-therapeutics-inc-nasdaqplrx-a-promising-biopharmaceutical-company-advancing-novel-therapies-for...
MikeTester - August 3, 2024
View more Bullboard ››

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds the Summit Gold ...
View More »